AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants
Authors: Lu, J Kuritzkes, DR
Citation: J. Lu et Dr. Kuritzkes, A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants, J ACQ IMM D, 27(1), 2001, pp. 7-13
Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity
Authors: Stubbs, AC Martin, KS Coeshott, C Skaates, SV Kuritzkes, DR Bellgrau, D Franzusoff, A Duke, RC Wilson, CC
Citation: Ac. Stubbs et al., Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity, NAT MED, 7(5), 2001, pp. 625-629
Multiple CD4(+) cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highlyactive antiretroviral therapy
Authors: Wu, HL Connick, E Kuritzkes, DR Landay, A Spritzler, J Zhang, B Spear, GT Kessler, H Lederman, MM
Citation: Hl. Wu et al., Multiple CD4(+) cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highlyactive antiretroviral therapy, AIDS RES H, 17(13), 2001, pp. 1231-1240
Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome
Authors: Kosmiski, LA Kuritzkes, DR Lichtenstein, KA Glueck, DH Gourley, PJ Stamm, ER Scherzinger, AL Eckel, RH
Citation: La. Kosmiski et al., Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome, AIDS, 15(15), 2001, pp. 1993-2000
Virologic and regimen termination surrogate end points in AIDS clinical trials
Authors: Gilbert, PB DeGruttola, V Hammer, SM Kuritzkes, DR
Citation: Pb. Gilbert et al., Virologic and regimen termination surrogate end points in AIDS clinical trials, J AM MED A, 285(6), 2001, pp. 777-784
A fossil record of zidovudine resistance in transmitted isolates of HIV-1
Authors: Kuritzkes, DR
Citation: Dr. Kuritzkes, A fossil record of zidovudine resistance in transmitted isolates of HIV-1, P NAS US, 98(24), 2001, pp. 13485-13487
Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion
Authors: Connick, E Schlichtemeier, RL Purner, MB Schneider, KM Anderson, DM MaWhinney, S Campbell, TB Kuritzkes, DR Douglas, JM Judson, FN Schooley, RT
Citation: E. Connick et al., Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion, J INFEC DIS, 184(11), 2001, pp. 1465-1469
Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates
Authors: Duan, CY Poticha, D Stoeckli, TC Petropoulos, CJ Whitcomb, JM McHenry, CS Kuritzkes, DR
Citation: Cy. Duan et al., Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates, J INFEC DIS, 184(10), 2001, pp. 1336-1340
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373
Authors: Gulick, RM Smeaton, LM D'Aquila, RT Eron, JJ Currier, JS Gerber, JG Acosta, E Sommadossi, JP Tung, R Snyder, S Kuritzkes, DR Murphy, RL
Citation: Rm. Gulick et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373, J INFEC DIS, 183(5), 2001, pp. 715-721
Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
Authors: Picchio, GR Valdez, H Sabbe, R Landay, AL Kuritzkes, DR Lederman, MM Mosier, DE
Citation: Gr. Picchio et al., Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy, J ACQ IMM D, 25(4), 2000, pp. 289-295
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
Authors: Kuritzkes, DR Shugarts, D Bakhtiari, M Poticha, D Johnson, J Rubin, M Gingeras, TR Kennedy, M Eron, JJ
Citation: Dr. Kuritzkes et al., Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy, J ACQ IMM D, 23(1), 2000, pp. 26-34
Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor
Authors: Kuritzkes, DR
Citation: Dr. Kuritzkes, Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: The role of granulocyte colony-stimulating factor, CLIN INF D, 30(2), 2000, pp. 256-260
Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens
Authors: Gilbert, PB Hanna, GJ De Gruttola, V Martinez-Picado, J Kuritzkes, DR Johnson, VA Richman, DD D'Aquila, RT
Citation: Pb. Gilbert et al., Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens, AIDS RES H, 16(14), 2000, pp. 1325-1336
Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial
Authors: Gilbert, PB Ribaudo, HJ Greenberg, L Yu, G Bosch, RJ Tierney, C Kuritzkes, DR
Citation: Pb. Gilbert et al., Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial, AIDS, 14(13), 2000, pp. 1961-1972
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370
Authors: Kuritzkes, DR Bassett, RL Johnson, VA Marschner, IC Eron, JJ Sommadossi, JP Acosta, EP Murphy, RL Fife, K Wood, K Bell, D Martinez, A Pettinelli, CB
Citation: Dr. Kuritzkes et al., Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370, AIDS, 14(11), 2000, pp. 1553-1561
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
Authors: Valdez, H Smith, KY Landay, A Connick, E Kuritzkes, DR Kessler, H Fox, L Spritzler, J Roe, J Lederman, MB Lederman, HM Evans, TG Heath-Chiozzi, M Lederman, MM
Citation: H. Valdez et al., Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen, AIDS, 14(1), 2000, pp. 11-21
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
Authors: Precious, HM Gunthard, HF Wong, JK D'Aquila, RT Johnson, VA Kuritzkes, DR Richman, DD Brown, AJL
Citation: Hm. Precious et al., Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy, AIDS, 14(1), 2000, pp. 31-36
Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel
Authors: Hirsch, MS Brun-Vezinet, F D'Aquila, RT Hammer, SM Johnson, VA Kuritzkes, DR Loveday, C Mellors, JW Clotet, B Conway, B Demeter, LM Vella, S Jacobsen, DM Richman, DD
Citation: Ms. Hirsch et al., Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel, J AM MED A, 283(18), 2000, pp. 2417-2426
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase
Authors: Hanna, GJ Johnson, VA Kuritzkes, DR Richman, DD Martinez-Picado, J Sutton, L Hazelwood, JD D'Aquila, RT
Citation: Gj. Hanna et al., Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase, J CLIN MICR, 38(7), 2000, pp. 2715-2721
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine
Authors: Hanna, GJ Johnson, VA Kuritzkes, DR Richman, DD Brown, AJL Savara, AV Hazelwood, JD D'Aquila, RT
Citation: Gj. Hanna et al., Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine, J INFEC DIS, 181(3), 2000, pp. 904-911
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group protocol 315
Authors: Kuritzkes, DR Sevin, A Young, B Bakhtiari, M Wu, HL St Clair, M Connick, E Landay, A Spritzler, J Kessler, H Lederman, MM
Citation: Dr. Kuritzkes et al., Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group protocol 315, J INFEC DIS, 181(2), 2000, pp. 491-497
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
Authors: Connick, E Lederman, MM Kotzin, BL Spritzler, J Kuritzkes, DR St Clair, M Sevin, AD Fox, L Chiozzi, MH Leonard, JM Rousseau, F Roe, JD Martinez, A Kessler, H Landay, A
Citation: E. Connick et al., Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response, J INFEC DIS, 181(1), 2000, pp. 358-363
Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells
Authors: Campbell, TB Sevin, A Coombs, RW Peterson, GC Rosandich, M Kuritzkes, DR Mladenovic, J Landay, A Wong, R Ambruso, D Miles, S Pomerantz, RJ Schooley, RT
Citation: Tb. Campbell et al., Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells, BLOOD, 95(1), 2000, pp. 48-55
Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases
Authors: Marschner, IC Betensky, RA DeGruttola, V Hammer, SM Kuritzkes, DR
Citation: Ic. Marschner et al., Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases, J ACQ IMM D, 20(3), 1999, pp. 220-227
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4(+) and CD8(+) T cells
Authors: Kaushal, S Landay, AL Lederman, MM Connick, E Spritzler, J Kuritzkes, DR Kessler, H Levine, BL St Louis, DC June, CH
Citation: S. Kaushal et al., Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4(+) and CD8(+) T cells, CLIN IMMUNO, 92(1), 1999, pp. 14-24
Risultati: 1-25 | 26-36